Sales of oral contraceptive products increased 13.9 percent, helped by a 93.8 percent rise in filled prescriptions for Loestrin 24 FE. ...
... said Friday it swung to a fourth-quarter profit as sales of contraceptive Loestrin 24 FE and plaque psoriasis medication Taclonex helped drive revenue.
NEW YORK (Associated Press) - Drug maker Warner Chilcott Ltd. said Friday it swung to a fourth-quarter profit as sales of contraceptive Loestrin 24 FE and ...
... said Friday it swung to a fourth-quarter profit as sales of contraceptive Loestrin 24 FE and plaque psoriasis medication Taclonex helped drive revenue.
... said Friday it swung to a fourth-quarter profit as sales of contraceptive Loestrin 24 FE and plaque psoriasis medication Taclonex helped drive revenue.
The primary drivers of the increase in revenue for both periods were the net sales of two products, LOESTRIN 24 FE and TACLONEX, which together contributed ...
... said Friday it swung to a fourth-quarter profit as sales of contraceptive Loestrin 24 FE and plaque psoriasis medication Taclonex helped drive revenue.
all 9 news articles
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...